A potential treatment for heart attack and stroke, derived from a spider venom molecule identified by University of Queensland researchers, has been administered to the first participants in a clinical trial. The phase 1 study, currently underway, will assess the safety, tolerability and dosage of IB409, a novel drug developed by Brisbane-based biotechnology company Infensa Bioscience. Professor Glenn King from UQ’s Institute for Molecular Bioscience said his team had publi

One of the world’s leading healthcare companies has completed its acquisition of the biopharmaceutical company commercialising The University of Queensland's Molecular Clamp technology.

A cancer-targeting antibody that helps the body’s immune cells spot and destroy hard-to-treat tumours such as triple-negative breast cancer has been developed by researchers.

Prof John Hooper (image courtesy: Uniquest) The Australian National Imaging Facility and Therapeutic Innovation Australia have supported development of a promising new ovarian cancer drug from early-stage development, through preclinical studies and now its first in-human studies. Ovarian cancer is dubbed ‘the silent killer’ due to its vague early symptoms and late diagnosis – resulting in a high mortality rate – and this is compounded by a lack of new drugs and clinical deve

Researchers at the University of Queensland’s Australian Institute for Bioengineering and Nanotechnology are working to develop a vaccine in just 100 days to support future pandemic preparedness.